During times of turbulence and uncertainty in the markets, many investors turn to dividend-yielding stocks. These are often companies that have high free cash flows and reward shareholders with a high dividend payout.
Benzinga readers can review the latest analyst takes on their favorite stocks by visiting Analyst Stock Ratings page. Traders can sort through Benzinga’s extensive database of analyst ratings, including by analyst accuracy.
Below are the ratings of the most accurate analysts for three high-yielding stocks in the health care sector.
Pfizer Inc. (NYSE:PFE)
- Dividend Yield: 6.79%
- Guggenheim analyst Vamil Divan reiterated a Buy rating on March 18, 2025. This analyst has an accuracy rate of 73%.
- Citigroup analyst Andrew Baum maintained a Neutral rating and cut the price target from $30 to $29 on Jan. 28, 2025. This analyst has an accuracy rate of 69%.
- Recent News: On June 26, Pfizer announced positive topline Phase 3 results for HYMPAVZI™ in Hemophilia …
Full story available on Benzinga.com
During times of turbulence and uncertainty in the markets, many investors turn to dividend-yielding stocks. These are often companies that have high free cash flows and reward shareholders with a high dividend payout.
Benzinga readers can review the latest analyst takes on their favorite stocks by visiting Analyst Stock Ratings page. Traders can sort through Benzinga’s extensive database of analyst ratings, including by analyst accuracy.
Below are the ratings of the most accurate analysts for three high-yielding stocks in the health care sector.
Pfizer Inc. (NYSE:PFE)
- Dividend Yield: 6.79%
- Guggenheim analyst Vamil Divan reiterated a Buy rating on March 18, 2025. This analyst has an accuracy rate of 73%.
- Citigroup analyst Andrew Baum maintained a Neutral rating and cut the price target from $30 to $29 on Jan. 28, 2025. This analyst has an accuracy rate of 69%.
- Recent News: On June 26, Pfizer announced positive topline Phase 3 results for HYMPAVZI™ in Hemophilia …
Full story available on Benzinga.com
During times of turbulence and uncertainty in the markets, many investors turn to dividend-yielding stocks. These are often companies that have high free cash flows and reward shareholders with a high dividend payout.
Benzinga readers can review the latest analyst takes on their favorite stocks by visiting Analyst Stock Ratings page. Traders can sort through Benzinga’s extensive database of analyst ratings, including by analyst accuracy.
Below are the ratings of the most accurate analysts for three high-yielding stocks in the health care sector.
Pfizer Inc. (NYSE:PFE)
Dividend Yield: 6.79%
Guggenheim analyst Vamil Divan reiterated a Buy rating on March 18, 2025. This analyst has an accuracy rate of 73%.
Citigroup analyst Andrew Baum maintained a Neutral rating and cut the price target from $30 to $29 on Jan. 28, 2025. This analyst has an accuracy rate of 69%.
Recent News: On June 26, Pfizer announced positive topline Phase 3 results for HYMPAVZI™ in Hemophilia …Full story available on Benzinga.com Read MoreCVS, dividend yield, Expert Ideas, health care, Long Ideas, MRK, News, PFE, Pro Project, Wall Street’s Most Accurate Analysts, Dividends, Price Target, Pre-Market Outlook, Markets, Analyst Ratings, Trading Ideas, CVS, US1266501006, MRK, US58933Y1055, PFE, US7170811035, Long Ideas, News, Dividends, Price Target, Pre-Market Outlook, Markets, Analyst Ratings, Trading Ideas, Benzinga Markets
